Prestige Consumer Healthcare (NYSE:PBH) Rating Increased to Moderate Buy at Raymond James

Raymond James upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) to a moderate buy rating in a report published on Thursday,Zacks.com reports.

A number of other brokerages have also commented on PBH. DA Davidson reissued a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $78.72 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The firm has a market cap of $3.89 billion, a PE ratio of 19.15, a PEG ratio of 2.32 and a beta of 0.49. The firm’s 50 day moving average price is $79.25 and its 200 day moving average price is $73.04. Prestige Consumer Healthcare has a twelve month low of $57.95 and a twelve month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 EPS. As a group, research analysts expect that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 over the last three months. 1.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC boosted its position in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares in the last quarter. nVerses Capital LLC raised its position in Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the last quarter. Huntington National Bank boosted its stake in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC grew its holdings in shares of Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after purchasing an additional 1,138 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.